The Need for New Tuberculosis Treatments Amidst Rising Antibiotic Resistance

Overview of Tuberculosis and Its Challenges

The rise of antibiotic-resistant strains of tuberculosis (TB) has intensified the need for new treatment options. TB, a bacterial infection, remains one of the leading causes of mortality worldwide, despite being treatable with antibiotics. However, the emergence of resistant strains of Mycobacterium tuberculosis has diminished the effectiveness of many standard medications. As a result, patients are often subjected to extended treatment protocols that are not only more costly but also carry increased toxicity, with some facing forms of the disease that are deemed untreatable.

Understanding Antibiotic Resistance in Tuberculosis

Most bacteria in nature do not possess inherent resistance to antibiotics, primarily due to the metabolic costs associated with developing such resistance, which can impair their growth. However, TB patients typically undergo long-term antibiotic treatment. During this time, while standard bacteria are eradicated, any pre-existing antibiotic-resistant variants are allowed to thrive. A single mutated M. tuberculosis bacterium can replicate and dominate the infection, ultimately leading to treatment failure.

Innovative Treatment Approaches

A novel therapeutic strategy aims to tackle TB infections by disrupting the bacteria’s capacity to invade and persist within immune cells. This approach focuses on identifying drugs that can limit the infectivity of M. tuberculosis without necessarily killing the bacteria. The objective is to accelerate treatment and reduce the spread of resistance. Recent studies conducted by researchers in the UK and the US have investigated a promising new drug, with results published in the Journal of Medicinal Chemistry.

Research Findings on MptpB Protein

The research concentrated on MptpB, a specific protein that M. tuberculosis uses to evade the immune response. The team tested various compounds to inhibit the function of MptpB and discovered one particularly effective candidate. This new drug significantly impaired the bacterium’s ability to infect immune cells in laboratory settings, achieving this without killing the bacteria. This property suggests a potential to avoid further promoting antibiotic resistance and may enhance the effectiveness of existing antibiotics.

Testing in Animal Models

Following laboratory success, the new drug was administered to guinea pigs infected with M. tuberculosis. Although it did not perform as effectively as traditional antibiotics, it notably reduced the severity of the infection.

Future Prospects for the New Treatment

To evaluate the drug’s effectiveness against antibiotic-resistant strains, researchers opted for in vitro testing on immune cells to mitigate the risk of laboratory contamination. The findings indicated that the drug could effectively limit the infection capabilities of antibiotic-resistant M. tuberculosis.

Next Steps in Drug Development

Transitioning from animal studies to human trials involves critical steps. The drug requires further optimization for improved efficacy, followed by safety assessments in human subjects. Actual clinical trials with TB patients may take several years to commence.

Conclusion and Optimism for the Future

Despite the challenges that lie ahead, researchers are optimistic that such innovative drugs could play a significant role in addressing the issue of antibiotic-resistant tuberculosis. Moreover, the methodologies developed may also be applicable in treating other severe infections, including C. difficile.

References

Vickers, C. F., Silva, A. P. G., Chakraborty, A., Fernandez, P., Kurepina, N., Saville, C., Naranjo, Y., Pons, M., Schnettger, L. S., Gutierrez, M. G., Park, S., Kreiswith, B. N., Perlin, D. S., Thomas, E. J., Cavet, J. S. & Tabernero, L. Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo. Journal of Medicinal Chemistry 61, 8337-8352 (2018).

Tuberculosis Fact Sheet. World Health Organization (2018). http://www.who.int/en/news-room/fact-sheets/detail/tuberculosis. Accessed October 2018.

The University of Manchester. Scientists develop new drug treatment for TB. https://www.manchester.ac.uk/discover/news/scientists-develop-new-drug-treatment-for-tb/. Accessed October 2018.